Patent ID: 8877175
Filing Date: 2014-11-04
Classification: A61K,A61P,C07K,C12N

Abstract:
1. A method of treating anemia in a human subject in need over a sustained time period comprising the steps of: (a) providing at least one autologous erythropoietin secreting genetically modified dermal micro-organ that comprises a helper-dependent adenovirus vector comprising the nucleic acid sequence encoding erythropoietin operably linked to one or more regulatory sequences, wherein said nucleic acid comprises SEQ ID NO: 11, (b) determining the erythropoietin secretion levels of the at least one genetically modified dermal micro-organ in step (a) in vitro, (c) implanting the autologous genetically modified dermal micro-organ of step (b) in said human subject at an effective dosage at a site selected from the group consisting of subcutaneously, subdermally and intradermally, (d) measuring hemoglobin levels in the blood of said human subject from step (c); and (e) maintaining hemoglobin levels in said human subject at 9-11 g/dl in at least 50% of the measurements for at least one month, thereby treating anemia in a human subject.